This years summit will equip you with the most up to date time and money saving tools such as new In silico models and In vitro methods.
The event will be thought provoking, asking important questions on the predictive ability of new research subjects such as stem cells and 3D models.
Industry case studies and research presentations will be used to illustrate the current state of predictive toxicology testing and emerging testing tools in areas such as liver toxicity. Predictive testing will be covered with emphasis on clinical studies in several therapeutic areas including neuroscience, liver toxicity, oncology and cardio toxicity.
The 7th Annual Predictive Toxicology Summit is your tool kit to the forthcoming drug development year covering topics such as:
The transition of the Toxicology industry from animal models to human tissue models
The evolution of 3D Models
Stem cells
Biomarkers
The power of predictive Toxicology is not to be underestimated as it is one of the most important stages in drug development, it reduces the number of late stage drug attrition by highlighting toxicity at an earlier stage in drug development.
Now widely regarded as not only a necessary stage but a compulsory stage in drug development, the need for more predictive and accurate testing practices is building. Although some predictive tests have high up front costs, it is estimated that the cost of developing a new drug is £500m and so the possible savings are vast.
The event will be thought provoking, asking important questions on the predictive ability of new research subjects such as stem cells and 3D models.
Industry case studies and research presentations will be used to illustrate the current state of predictive toxicology testing and emerging testing tools in areas such as liver toxicity. Predictive testing will be covered with emphasis on clinical studies in several therapeutic areas including neuroscience, liver toxicity, oncology and cardio toxicity.
The 7th Annual Predictive Toxicology Summit is your tool kit to the forthcoming drug development year covering topics such as:
The transition of the Toxicology industry from animal models to human tissue models
The evolution of 3D Models
Stem cells
Biomarkers
The power of predictive Toxicology is not to be underestimated as it is one of the most important stages in drug development, it reduces the number of late stage drug attrition by highlighting toxicity at an earlier stage in drug development.
Now widely regarded as not only a necessary stage but a compulsory stage in drug development, the need for more predictive and accurate testing practices is building. Although some predictive tests have high up front costs, it is estimated that the cost of developing a new drug is £500m and so the possible savings are vast.
